The candesartan cilexetil drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Candesartan is an insulin-like growth factor enzyme inhibitor (ACEI) that can be used alone or in combination with other agents to treat hypertension. It is taken orally as the prodrug candesartan cilexetil, which is rapidly converted to the active metabolite candesartan in the gastrointestinal tract during absorption. Candesartan works by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype, preventing angiotensin II’s blood pressure-raising effects. angiotensin-receptor blockers (ARBs), unlike angiotensin-converting enzyme (ACE) inhibitors, do not cause dry cough. Hypertension, isolated systolic hypertension, left ventricular hypertrophy, and diabetic nephropathy is among conditions that can be treated with candesartan. It can also be used to treat heart failure and systolic dysfunction as an alternate treatment.
A full report of Candesartan Cilexetil Drug Market is available at:https://orionmarketreports.com/candesartan-cilexetil-drug-market-2/98284/
Candesartan cilexetil is an angiotensin-receptor blocker (ARB) prodrug that is rapidly converted to candesartan, the active metabolite, in the gastrointestinal system after absorption. By antagonizing the hypertensive effects of angiotensin II throughthe RAAS, candesartan lowers blood pressure. The RAAS system regulates hemodynamic, water, and electrolyte balance in the body. Renin is released by granular cells of the juxtaglomerular apparatus in the kidneys after sympathetic stimulation or when renal blood pressure or blood flow is lowered. Renin converts circulating angiotensinogen to angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme (ACE).
Angiotensin II raises blood pressure by modifying the cardiovascular structure and raising total peripheral resistance. It also increases sodium and water reabsorption in the kidneys via aldosterone release. The absolute bioavailability of candesartan was calculated to be 15% after administration of the candesartan cilexetil prodrug. The bioavailability of candesartan from candesartan cilexetil is unaffected by high-fat foods.Type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2) are the two receptors that angiotensin II binds to (AT2). Angiotensin II’s vasoconstrictive and aldosterone-secreting effects are mediated by AT1, a G-protein coupled receptor (GPCR). AT2 antagonises AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape-Mylan NV, Teva Pharmaceutical Industries Ltd., and ANI Pharmaceuticals, Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Candesartan Cilexetil Drug Market Report by Segment
By Type
- 4 mg Tablets
- 8 mg Tablets
- 16 mg Tablets
- 32 mg Tablets
By Application
- Essential Hypertension in Adults
- Hypertension in Children and Adolescents Aged 6 to 18 Years
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
